Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–263 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: First Intervention (14 days) Clear all
Terminated Not applicable Interventional Results available

Clinical Management of Neuropathic Pain With Ramelteon

NCT00753623
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 11, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 11, 2026, 5:42 AM EDT
Recruiting Not applicable Interventional

Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques

NCT06892496
View directory record Official record
Conditions
Mucosal Erosion, Gingival Recession
Interventions
Visual Analog scale (VAS) questionnaire, Vacuum-formed retainer (VFR) technique, 3-D printed acrylic resin stent (3DS) technique, Flowable resin composite stent (FRC) technique, Photographs of the patient's palate, Measuring graft dimensions, Chairside Polymer Stent
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

Identifying Optimal Smoking Cessation Intervention Components (Cessation)

NCT01116986
View directory record Official record
Conditions
Smoking, Smoking Cessation, Nicotine Dependence
Interventions
Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive in-person counseling during the quit attempt, Minimal phone counseling during the quit attempt, Intensive phone counseling during the quit attempt, Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt, Short Term Nicotine Patch + Nicotine Gum during the quit attempt, Pre-Quit Nicotine Gum, Pre-Quit Nicotine Patch, Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy

NCT00593242
View directory record Official record
Conditions
Neonatal Hypoxic Ischemic Encephalopathy
Interventions
infusion of autologous cord blood, Neurodevelopmental outcomes
Biological · Other
Lead sponsor
Michael Cotten
Other
Eligibility
Up to 14 Days
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Adoptive Transfer of Haploidentical NK Cells and N-803

NCT03899480
View directory record Official record
Conditions
Hiv, HIV Infections, Immune Deficiency
Interventions
Haploidentical Natural Killer (NK) Cells
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 11, 2026, 5:42 AM EDT
Active, not recruiting Phase 2 Interventional

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions
Obinutuzumab, Glofitamab
Drug
Lead sponsor
Reid Merryman, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03081858
View directory record Official record
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 11, 2026, 5:42 AM EDT
Recruiting Phase 1 Interventional

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

NCT04157127
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Interventions
Autologous DC Therapy
Biological
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

NCT02387203
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms
Interventions
PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Drug
Lead sponsor
Mercy Medical Center
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00816283
View directory record Official record
Conditions
Leukemia
Interventions
dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 11, 2026, 5:42 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Decision Support Tool to Integrate PrEP Into Emergency Departments

NCT07279129
View directory record Official record
Conditions
HIV
Interventions
Decision support tool, PrEP Delivery
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Not applicable Interventional Results available

Foot and Ankle Post-operative Oedema Management Using Geko™

NCT04927234
View directory record Official record
Conditions
Surgery, Edema
Interventions
geko™ therapy
Device
Lead sponsor
Firstkind Ltd
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Capitola, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Cervical "STRETCH" Study

NCT07440030
View directory record Official record
Conditions
Cervical Spine
Interventions
Guided Cervical Stretching Regimen
Behavioral
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Extended Wear Technology

NCT04882800
View directory record Official record
Conditions
Hearing Loss
Interventions
Lyric extended wear hearing aid device A, Lyric extended wear hearing aid with fitting modification device B
Device
Lead sponsor
Sonova AG
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Narberth, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 11, 2026, 5:42 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid

NCT07694492
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder, Nicotine Dependence, Smokeless Tobacco Use
Interventions
QuitAid (pharmacist-delivered MTM), Nicotine Replacement Therapy (NRT)
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

NCT04436744
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant, Anastrozole, Palbociclib, Surgery
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 11, 2026, 5:42 AM EDT
Not listed Phase 2 Interventional

Project RAP: Reaching Adolescents for Prevention

NCT00183157
View directory record Official record
Conditions
Alcohol Related Morbidity, Alcohol Dependence
Interventions
Brief Motivational Intervention, Assessment and list of resources, Referral to Community Resources
Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
14 Years to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Oct 11, 2026, 5:42 AM EDT
Active, not recruiting Phase 2 Interventional

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

NCT05020912
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
ALA, PDT
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 11, 2026, 5:42 AM EDT
Terminated Phase 1 Interventional

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

NCT03976050
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
HL-085
Drug
Lead sponsor
Shanghai Kechow Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 11, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

NCT03753243
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide
Drug
Lead sponsor
Mark Garzotto, MD
Federal
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 11, 2026, 5:42 AM EDT